{"id":344549,"date":"2026-11-12T10:36:11","date_gmt":"2026-11-12T05:06:11","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=344549"},"modified":"2026-11-12T10:36:11","modified_gmt":"2026-11-12T05:06:11","slug":"engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/","title":{"rendered":"3 Engineering Consultancy Company, Hotels Company and Pharmaceutical Maker Stocks With a Strong Future Roadmap: Engineers India, Lemon Tree Hotels and Lupin"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Engineers India, Lemon Tree Hotels and Lupin: ROE of 16.3% to 23.8% and FY22 to FY26 revenue CAGR of 7.9% to 37.7%. Prices as of 11 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three engineering consultancy, hotel and pharma stocks to watch are Engineers India, Lemon Tree Hotels and Lupin. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 37.7%. Lupin has the highest return on equity at 23.8%, while Lemon Tree Hotels has the fastest revenue growth at 37.7% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Engineering consultancy, hotel and pharma stocks offer a focused view of a sector where demand keeps widening. Engineers India, Lemon Tree Hotels and Lupin cover an engineering consultancy company, a hotels company and a pharmaceutical maker.<\/p>\n<p>This list covers three engineering consultancy, hotel and pharma stocks with complete current figures: Engineers India, Lemon Tree Hotels and Lupin. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#What_Are_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"What Are Engineering Consultancy, Hotel and Pharma Stocks?\">What Are Engineering Consultancy, Hotel and Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Engineering_Consultancy_Hotel_and_Pharma_Stocks_at_a_Glance\" title=\"Engineering Consultancy, Hotel and Pharma Stocks at a Glance\">Engineering Consultancy, Hotel and Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Why_Do_Engineering_Consultancy_Hotel_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Engineering Consultancy, Hotel and Pharma Stocks Have a Strong Roadmap in India?\">Why Do Engineering Consultancy, Hotel and Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Why_Engineers_India_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"Why Engineers India Features Among These Engineering Consultancy, Hotel and Pharma Stocks\">Why Engineers India Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Why_Lemon_Tree_Hotels_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"Why Lemon Tree Hotels Features Among These Engineering Consultancy, Hotel and Pharma Stocks\">Why Lemon Tree Hotels Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Why_Lupin_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"Why Lupin Features Among These Engineering Consultancy, Hotel and Pharma Stocks\">Why Lupin Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Engineers_India_vs_Lemon_Tree_Hotels_vs_Lupin_on_Key_Financials\" title=\"Engineers India vs Lemon Tree Hotels vs Lupin on Key Financials\">Engineers India vs Lemon Tree Hotels vs Lupin on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Key_Risks_to_Check_Before_Investing_in_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Engineering Consultancy, Hotel and Pharma Stocks\">Key Risks to Check Before Investing in Engineering Consultancy, Hotel and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Final_Thoughts_on_Engineering_Consultancy_Hotel_and_Pharma_Stocks\" title=\"Final Thoughts on Engineering Consultancy, Hotel and Pharma Stocks\">Final Thoughts on Engineering Consultancy, Hotel and Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#What_are_engineering_consultancy_hotel_and_pharma_stocks\" title=\"What are engineering consultancy, hotel and pharma stocks?\">What are engineering consultancy, hotel and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Which_engineering_consultancy_hotel_and_pharma_stocks_are_covered_in_this_list\" title=\"Which engineering consultancy, hotel and pharma stocks are covered in this list?\">Which engineering consultancy, hotel and pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Why_do_engineering_consultancy_hotel_and_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do engineering consultancy, hotel and pharma stocks have a strong future roadmap in India?\">Why do engineering consultancy, hotel and pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#How_has_Engineers_India_performed_financially\" title=\"How has Engineers India performed financially?\">How has Engineers India performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#How_has_Lemon_Tree_Hotels_performed_financially\" title=\"How has Lemon Tree Hotels performed financially?\">How has Lemon Tree Hotels performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#How_has_Lupin_performed_financially\" title=\"How has Lupin performed financially?\">How has Lupin performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#What_risks_should_investors_check_before_buying_engineering_consultancy_hotel_and_pharma_stocks\" title=\"What risks should investors check before buying engineering consultancy, hotel and pharma stocks?\">What risks should investors check before buying engineering consultancy, hotel and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks-roadmap-highland-list\/#Is_this_list_of_engineering_consultancy_hotel_and_pharma_stocks_investment_advice\" title=\"Is this list of engineering consultancy, hotel and pharma stocks investment advice?\">Is this list of engineering consultancy, hotel and pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>What Are Engineering Consultancy, Hotel and Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Engineering consultancy, hotel and pharma stocks are listed companies that design and manage refinery, petrochemical and infrastructure projects, run mid priced hotels across many cities, and make branded and generic medicines for India and global markets. Their earnings depend on project awards, hotel occupancy and prescription demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Engineering_Consultancy_Hotel_and_Pharma_Stocks_at_a_Glance\"><\/span><strong>Engineering Consultancy, Hotel and Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/enginersin\/engineers-india-ltd-share-price-today\">Engineers India<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">311.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,096<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.01<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lemontree\/lemon-tree-hotels-ltd-share-price-today\">Lemon Tree Hotels<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">115.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8,849<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.44<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,023.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">89,343<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.29<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing engineering consultancy, hotel and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Engineering_Consultancy_Hotel_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Engineering Consultancy, Hotel and Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Engineering consultancy, hotel and pharma stocks have a strong roadmap in India because continued investment in refining and infrastructure, growing domestic travel and rising demand for quality medicines keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Engineering consultancy.<\/strong> Large plants need expert design and oversight.<\/li>\n<li><strong>Hotels.<\/strong> Business and leisure travel keep rooms busy.<\/li>\n<li><strong>Pharma.<\/strong> Generic and branded medicines reach more markets.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Engineers_India_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>Why Engineers India Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the engineering consultancy, hotel and pharma stocks on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.<\/p>\n<p>Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.<\/p>\n<p>The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7.<\/p>\n<p><strong>Roadmap:<\/strong> The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<p><strong>What to watch:<\/strong> Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Lemon_Tree_Hotels_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>Why Lemon Tree Hotels Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the plant design, mid price stay and medicine shares on this list, Lemon Tree Hotels is one of India&#8217;s largest mid-priced hotel chains, operating and managing hotels under the Lemon Tree, Red Fox, Aurika and Keys brands.<\/p>\n<p>In the June 2026 quarter, revenue grew 9.2% year on year to Rs 347 crore, while net profit rose 19.2% to Rs 57.3 crore. Revenue rose from Rs 408 crore in FY22 to Rs 1,465 crore in FY26, a compound annual growth rate of 37.7%.<\/p>\n<p>Net profit grew from Rs 141 crore in FY23 to Rs 288 crore in FY26, which works out to a compound annual growth rate of 27.1%. The company has a return on equity of 16.3%, a debt to equity ratio of 1.44 and a market capitalisation of Rs 8,849 crore. The stock trades at a P\/E of 29.7, below the industry P\/E of 37.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company is adding rooms mainly through management contracts, which grow its footprint with limited capital outlay. Rising domestic travel and a focus on the mid-priced segment support healthy occupancy.<\/p>\n<p><strong>What to watch:<\/strong> Monitor new room signings and openings and average room rate trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Lupin_Features_Among_These_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>Why Lupin Features Among These Engineering Consultancy, Hotel and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.<\/p>\n<p>The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.<\/p>\n<p><strong>What to watch:<\/strong> Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Engineers_India_vs_Lemon_Tree_Hotels_vs_Lupin_on_Key_Financials\"><\/span><strong>Engineers India vs Lemon Tree Hotels vs Lupin on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three engineering consultancy, hotel and pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Engineers India<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,043<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,123<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">692<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Lemon Tree Hotels<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">408<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,465<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">37.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">288<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Lupin<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,616<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,039<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,355<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Lemon Tree Hotels shows the fastest revenue growth with a 37.7% compound annual rate. A useful habit with engineering consultancy, hotel and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Engineering Consultancy, Hotel and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these engineering consultancy, hotel and pharma stocks, the main points are: Long-term plant design, mid price stay and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Order timing.<\/strong> Project awards can shift between periods.<\/li>\n<li><strong>Travel cycles.<\/strong> Bookings and occupancy follow travel demand.<\/li>\n<li><strong>Pricing pressure.<\/strong> Generic prices can change by market.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter engineering consultancy, hotel and pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Engineering_Consultancy_Hotel_and_Pharma_Stocks\"><\/span><strong>Final Thoughts on Engineering Consultancy, Hotel and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Engineering consultancy, hotel and pharma stocks reward patient research into demand, execution and financial strength. Engineers India, Lemon Tree Hotels and Lupin each have a clear plan to grow. Based on the 11 November 2026 close, Engineers India trades at Rs 311.2, Lemon Tree Hotels at Rs 115.1 and Lupin at Rs 2,023.4. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these engineering consultancy, hotel and pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track engineering consultancy, hotel and pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_engineering_consultancy_hotel_and_pharma_stocks\"><\/span><strong>What are engineering consultancy, hotel and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Engineering consultancy, hotel and pharma stocks are listed companies that design and manage refinery, petrochemical and infrastructure projects, run mid priced hotels across many cities, and make branded and generic medicines for India and global markets. Their earnings depend on project awards, hotel occupancy and prescription demand. This list looks at three of them, Engineers India, Lemon Tree Hotels and Lupin, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_engineering_consultancy_hotel_and_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which engineering consultancy, hotel and pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Engineers India, Lemon Tree Hotels and Lupin. Based on the 11 November 2026 close, Engineers India traded at Rs 311.2, Lemon Tree Hotels at Rs 115.1 and Lupin at Rs 2,023.4. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 37.7%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_engineering_consultancy_hotel_and_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do engineering consultancy, hotel and pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Engineering consultancy, hotel and pharma stocks have a strong roadmap in India because continued investment in refining and infrastructure, growing domestic travel and rising demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Engineering consultancy. Large plants need expert design and oversight. Hotels. Business and leisure travel keep rooms busy. Pharma. Generic and branded medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Engineers_India_performed_financially\"><\/span><strong>How has Engineers India performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Lemon_Tree_Hotels_performed_financially\"><\/span><strong>How has Lemon Tree Hotels performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 408 crore in FY22 to Rs 1,465 crore in FY26, a compound annual growth rate of 37.7%. Net profit grew from Rs 141 crore in FY23 to Rs 288 crore in FY26, which works out to a compound annual growth rate of 27.1%. In the June 2026 quarter, revenue grew 9.2% year on year to Rs 347 crore, while net profit rose 19.2% to Rs 57.3 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 1.44 and a market capitalisation of Rs 8,849 crore. The stock trades at a P\/E of 29.7, below the industry P\/E of 37.9. Looking ahead, the company is adding rooms mainly through management contracts, which grow its footprint with limited capital outlay. Rising domestic travel and a focus on the mid-priced segment support healthy occupancy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Lupin_performed_financially\"><\/span><strong>How has Lupin performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_engineering_consultancy_hotel_and_pharma_stocks\"><\/span><strong>What risks should investors check before buying engineering consultancy, hotel and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying engineering consultancy, hotel and pharma stocks. Order timing. Project awards can shift between periods. Travel cycles. Bookings and occupancy follow travel demand. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_engineering_consultancy_hotel_and_pharma_stocks_investment_advice\"><\/span><strong>Is this list of engineering consultancy, hotel and pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are engineering consultancy, hotel and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Engineering consultancy, hotel and pharma stocks are listed companies that design and manage refinery, petrochemical and infrastructure projects, run mid priced hotels across many cities, and make branded and generic medicines for India and global markets. Their earnings depend on project awards, hotel occupancy and prescription demand. This list looks at three of them, Engineers India, Lemon Tree Hotels and Lupin, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which engineering consultancy, hotel and pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Engineers India, Lemon Tree Hotels and Lupin. Based on the 11 November 2026 close, Engineers India traded at Rs 311.2, Lemon Tree Hotels at Rs 115.1 and Lupin at Rs 2,023.4. Their return on equity ranges from 16.3% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 37.7%.\"}},{\"@type\":\"Question\",\"name\":\"Why do engineering consultancy, hotel and pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Engineering consultancy, hotel and pharma stocks have a strong roadmap in India because continued investment in refining and infrastructure, growing domestic travel and rising demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Engineering consultancy. Large plants need expert design and oversight. Hotels. Business and leisure travel keep rooms busy. Pharma. Generic and branded medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Engineers India performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P\/E of 19.2, below the industry P\/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.\"}},{\"@type\":\"Question\",\"name\":\"How has Lemon Tree Hotels performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 408 crore in FY22 to Rs 1,465 crore in FY26, a compound annual growth rate of 37.7%. Net profit grew from Rs 141 crore in FY23 to Rs 288 crore in FY26, which works out to a compound annual growth rate of 27.1%. In the June 2026 quarter, revenue grew 9.2% year on year to Rs 347 crore, while net profit rose 19.2% to Rs 57.3 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 1.44 and a market capitalisation of Rs 8,849 crore. The stock trades at a P\/E of 29.7, below the industry P\/E of 37.9. Looking ahead, the company is adding rooms mainly through management contracts, which grow its footprint with limited capital outlay. Rising domestic travel and a focus on the mid-priced segment support healthy occupancy.\"}},{\"@type\":\"Question\",\"name\":\"How has Lupin performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P\/E of 16.1, below the industry P\/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying engineering consultancy, hotel and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying engineering consultancy, hotel and pharma stocks. Order timing. Project awards can shift between periods. Travel cycles. Bookings and occupancy follow travel demand. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of engineering consultancy, hotel and pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Engineering Consultancy, Hotel and Pharma Stocks with a strong future roadmap: Engineers India, Lemon Tree Hotels and Lupin. Compare price, valuation, return on equity and revenue growth as of 11 November 2026.<\/p>\n","protected":false},"author":36,"featured_media":344548,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,22570,5971,22571,22575,7550,13958,22573,22572,22574],"class_list":["post-344549","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-engineering-consultancy","tag-engineers-india","tag-hotel-and-pharma-stocks","tag-hotel-chain-and-drug-maker-stocks","tag-lemon-tree-hotels","tag-lupin","tag-mid-price-stay-and-medicine-shares","tag-plant-design","tag-refinery-consultant"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["344548"],"rank_math_title":["Engineering Consultancy, Hotel and Pharma Stocks"],"rank_math_description":["Compare 3 engineering consultancy, hotel and pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 11 Nov 2026."],"rank_math_focus_keyword":["engineering consultancy, hotel and pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-engineering-consultancy-company-hotels-company-and-pharmaceutical-maker-stocks.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=344549"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344549\/revisions"}],"predecessor-version":[{"id":344550,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344549\/revisions\/344550"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/344548"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=344549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=344549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=344549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}